Register for a Live Webinar on Histotripsy

HistoSonics_Romance_Billboard01_Clipped-1-1

LIVE WEBINAR

Histotripsy for Patients with Limited Options: Clinical and Economic Impact

Histotripsy Mechanism of Action
Clinical utilization
Economic impact
Emerging evidence
Clinical trials & research

🗓️Thursday, March 26
🕔5:00 p.m. CST / 6:00 p.m. EST
🖥️Teams Webinar

SPEAKERS

Chase Wehrle, MD, Surgery | Cleveland Clinic
Young Hong, MD, Surgical Oncologist | Cooper University Health Care

MODERATOR
Joe Herman, MD, Medical Director | HistoSonics, Adjunct Professor | Zucker School of Medicine at Hofstra/Northwell

The countdown is complete

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

LIVE WEBINAR

Histotripsy for Patients with Limited Options: Clinical and Economic Impact

🗓️Thursday, March 26🕔5:00 p.m. CST / 6:00 p.m. EST🖥️Teams Webinar

SPEAKERS

🗓️Thursday, March 26
🕔5:00 p.m. CST / 6:00 p.m. EST
🖥️Teams Webinar